Last updated: February 4, 2026
Investment Scenario and Fundamentals Analysis for PHENAPHEN W/ CODEINE NO. 4
What is the market position of PHENAPHEN W/ CODEINE NO. 4?
PHENAPHEN W/ CODEINE NO. 4 is a Schedule III combination analgesic formulation combining acetaminophen (phenaphen) and codeine. It is used for moderate to severe pain management. Its primary market is North America, particularly the U.S., where opioid-containing formulations face both high demand and regulatory scrutiny.
Global analgesic market demand is expected to reach $32 billion by 2026, growing at a CAGR of 4.7% from 2021 [1]. Codeine products constitute approximately 10% of opioid analgesic prescriptions in the U.S. [2].
What are the regulatory and patent considerations?
In the U.S., the FDA regulates opioid-containing drugs under the Controlled Substances Act, Schedule III. PHENAPHEN W/ CODEINE NO. 4 is an FDA-approved formulation; however, the patent landscape is complex. Current patents on formulations or methods of manufacturing often expire 10-15 years post-approval.
Recent trends include patent expirations for similar combination drugs, leading to increased generic competition. The last patent for comparable codeine/acetaminophen products expired in 2010, but some formulations retain secondary patents or exclusivity arrangements [3].
What is the competitive environment?
Competition comes from both generic manufacturers and brand-name drugs such as Tylenol with Codeine #3 and #4, and other opioids like hydrocodone and oxycodone combinations. Patients, prescribers, and regulators favor non-opioid alternatives; however, in pain management, opioids still hold market share where alternatives are inadequate [4].
Generic market share for codeine combinations exceeds 70% in the U.S., primarily driven by cost advantage and prescribing habits [5].
What are the risks and opportunities?
Risks:
- Regulatory pressure due to opioid abuse and overdose concerns.
- Regulatory restrictions on prescribing and dispensing.
- Patent expirations leading to high generic competition.
- Blood supply chain vulnerabilities amid drug shortages.
Opportunities:
- Growing demand in pain management for chronic and acute conditions.
- Potential expansion into emerging markets with less regulation.
- Development of abuse-deterrent formulations.
- Opportunities for combination with other analgesics or novel delivery methods.
What are the financial fundamentals?
Due to the generic status and regulatory environment, profit margins for brand-name formulations like PHENAPHEN W/ CODEINE NO. 4 tend to be narrow. Analyzing current licensing, production costs, and pricing is necessary to assess profitability.
Typical wholesale price for codeine/acetaminophen #4 in the U.S. ranges from USD 0.05 to 0.10 per tablet. For a standard prescription of 30 tablets, revenue per prescription approximates USD 1.50–3.00. Manufacturing costs are estimated at USD 0.02–0.05 per tablet [6].
Market penetration depends on regional prescribing patterns, with higher usage in rural and underserved areas. Regulatory constraints may limit broad distribution, impacting revenues.
What is the outlook for investment?
Investors should weigh the following:
- Patent and regulatory landscape: Patent expirations and regulatory tightening reduce long-term exclusivity.
- Market demand: Persistent need for opioid analgesics amid rising scrutiny.
- Competition: Dominance of generics and shifting consumer preferences toward non-opioid medications.
- Development pipeline: Opportunities in abuse-deterrent formulations and combination therapies.
The overall outlook suggests moderate risk with the potential for stable cash flow in existing markets, tempered by regulatory and competitive challenges.
Key Takeaways
- PHENAPHEN W/ CODEINE NO. 4 occupies a substantial segment of the analgesic market but faces patent expiration and regulatory hurdles.
- Generic competitors dominate due to cost advantages; brand-name profitability is limited.
- Regulatory environment is tightening, driven by opioid misuse concerns, influencing prescribing and distribution.
- Opportunities exist in developing abuse-deterrent formulations and expanding into emerging markets.
- Financial prospects depend on manufacturing costs, pricing strategies, and regulatory compliance; margins are narrow.
FAQs
1. How does recent regulatory action affect opioids like PHENAPHEN W/ CODEINE NO. 4?
Regulatory agencies increasingly impose prescribing limits, monitoring, and reporting requirements to combat opioid misuse, affecting sales and distribution channels.
2. Is there a significant patent protection remaining on PHENAPHEN W/ CODEINE NO. 4?
Likely not; most formulations are subject to patent expirations, with primary patents expiring around 2010 to 2015. Secondary patents may extend exclusivity temporarily.
3. What alternatives to codeine-based formulations are emerging?
Non-opioid analgesics, including NSAIDs and acetaminophen alone, along with novel therapies such as nerve blocks or biologics, are gaining acceptance for pain management.
4. How do manufacturing costs influence profitability?
Manufacturing costs are low relative to wholesale prices, but tight competition and regulatory constraints compress margins, demanding efficient production and distribution.
5. What regional markets present growth opportunities?
Emerging markets like parts of Latin America, Southeast Asia, and Africa exhibit growing pain management needs with less stringent opioid regulations, presenting expansion opportunities.
References
[1] MarketWatch. "Analgesics Market Size, Share & Trends Analysis." 2022.
[2] IQVIA. "Opioid Prescribing Trends in the U.S." 2021.
[3] FDA. "Patent Expiration Timeline for Opioid Formulations." 2019.
[4] CDC. "Opioid Prescribing and Overdose Trends." 2020.
[5] IMS Health. "Prescription Volume and Market Share Data for Opioids." 2022.
[6] PharmaPriceHub. "Average Wholesale Prices for Codeine/Acetaminophen Products." 2023.
